Project Grant R44DK146369
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1M
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rockville, MD 20850, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Keybiome Inc. $1,287,812 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop AIMA, a protein-based therapeutic for inflammatory bowel disease. Keybiome is developing Aeromonas immune modulator (AIMA), an oral protein therapeutic that inhibits lipocalin 2 (LCN2), a pro-inflammatory and antimicrobial host protein elevated in IBD patients. AIMA...
- Federal Project Grant Award Summary Lactiga US Inc. received a $303,427 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2026. The award supports development of a proprietary therapeutic derived from human milk-based secretory IgA (sIgA) for oral delivery to treat Inflammatory Bowel Disease (IBD). The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $1,427,080 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate aberrant N-glycosylation in Crohn's disease as a pathway to precision medicine therapeutics. The research examines how defective N-glycosylation exacerbates Crohn's disease in patients carrying a pathogenic mutation in the manganese transporter ZIP8...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Washington $825,905 on March 6, 2026, to develop an immunocompetent colon chip platform for modeling Crohn's disease under CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research). The award funds construction of a three-dimensional intestinal platform incorporating primary intestinal and immune cells to model the colonic microenvironment in both health and disease. The platform...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Medosome Biotec LLC $356,251 on July 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop genetically engineered probiotics capable of producing and delivering glucagon-like peptide-1 (GLP-1) for treatment of metabolic diseases including type 2 diabetes and obesity. The project addresses limitations of existing GLP-1 receptor agonist therapies—poor patient...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Rutgers The State University of New Jersey $772,697 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate gut microbiome manipulation as a strategy to improve the efficacy and durability of anti-TNF therapies in inflammatory bowel disease. The project addresses treatment resistance in IBD patients by examining whether transplanting gut microbiota from...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital Inc. $193,776 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify cytokine biomarkers that predict response to IL-23 p19 inhibitor therapies for inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The research will quantify cytokines related to IL-23 signaling in serum and inflamed...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of California, Davis $180,109 on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate restoration of microbiota signaling pathways using non-biotic substitutes—termed "faux-biotics"—to control opportunistic infections during chemotherapy-induced dysbiosis. The project addresses the loss of colonization resistance that occurs...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $726,142 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of microbiota-specific T cells in inflammatory bowel disease. The research uses deep single-cell RNA and T cell receptor sequencing technologies to longitudinally profile T cell repertoire and phenotype in two parallel studies: human...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $803,565 to the University of California, Davis on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and characterize an orally delivered nanodrug for metabolic disease treatment. The project targets metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus by addressing gut dysbiosis and restoring impaired signaling...